{"id":810598,"date":"2025-02-07T15:00:05","date_gmt":"2025-02-07T20:00:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\/"},"modified":"2025-02-07T15:00:05","modified_gmt":"2025-02-07T20:00:05","slug":"tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\/","title":{"rendered":"Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell\u2122 Technology\u2019s Potential as a Scalable Medical Countermeasure"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WARREN, N.J., Feb.  07, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6DnVR-zdBD-6bRNkZGq_2-fN5yFmJBeTnK7ZcyLnPhkPqs5-Y6l_xA7k6Naun_OLk9dSLO4YCXKQqzpbUllY7Q==\" rel=\"nofollow\" target=\"_blank\">Tevogen Bio<\/a> (\u201cTevogen Bio Holdings Inc.\u201d or \u201cCompany\u201d) (Nasdaq: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ghW5v6p29add3aE2HT5KhK53hi2O5fo0ilMnvlaMxcFoWgqoqTtE2pKefJEUNr8utVPJOBIPFT4gDz6q2LZSRynub1CCD4sBODgsQHeABcE=\" rel=\"nofollow\" target=\"_blank\">TVGN<\/a>), a clinical-stage specialty immunotherapy biotech company, met the Center for the Biomedical Advanced Research and Development Authority (BARDA) TechWatch team. The discussion focused on Tevogen Bio\u2019s affordable and scalable ExacTcell technology, the positive results of its proof-of-concept (POC) clinical trial for TVGN 489, the use of Artificial Intelligence in its process and future manufacturing capabilities.<\/p>\n<p>During the meeting, Tevogen Bio discussed ExacTcell\u2019s unique ability to rapidly adapt to emerging viral threats, positioning it as a potential countermeasure to safeguard public health. Tevogen Bio will follow up with key federal entities and continue to update stakeholders.<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <strong>VITAL Biotech Accelerator Program<\/strong>\n        <\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>Department of Defense &#8211; Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense<\/strong>\n        <\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>Antivirals and Antitoxins Branch within BARDA\u2019s Division of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures<\/strong><br \/>\n          \n        <\/li>\n<\/ul>\n<p>\n        <strong>About Tevogen Bio<\/strong>\n      <\/p>\n<p>Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature\u2019s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Bio Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.<\/p>\n<p>Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio\u2019s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.<\/p>\n<p>\n        <strong>Contacts<\/strong>\n      <\/p>\n<p>Tevogen Bio Communications<br \/>T: 1 877 TEVOGEN, Ext 701 <br \/>Communications@Tevogen.com<\/p>\n<p>A video accompanying this announcement is available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UJqmJ7Aa9DT2TvumdNmyB7ZmrR-JA-iG3fygTh0Ni99_j6lMfxKauNggfQ-MCSc5RUjFVf7QFu7HqZ4AWpLXN2ow4idT8_QD6ryUvFSrKotFHAdFy9AWHIYSRTlNgP4dkwsn86TXsjwkU_WLA2pIhlVZOdwsYD8esM1TGYSPAY5uDXRCtWXc82E6XzXVr99Q9M8YAVJsUIibEj1jWe24nri7N73LMxsP6dmYlaDSoJ9ZsH1tpn5vJh5gVV1MtkF_091NJlKP5qLD6X7rwLZDjA==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/d566f0b7-923e-490e-b13f-50284c886cd7<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NTEwNiM2NzQxNjA5IzIyODk5MTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmY5MmJjYWUtNmExNS00YmE1LWI1YjgtMTYwYjFkYzhiMzViLTEzMDE0Njc=\/tiny\/Tevogen-Bio-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WARREN, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) &#8212; Tevogen Bio (\u201cTevogen Bio Holdings Inc.\u201d or \u201cCompany\u201d) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, met the Center for the Biomedical Advanced Research and Development Authority (BARDA) TechWatch team. The discussion focused on Tevogen Bio\u2019s affordable and scalable ExacTcell technology, the positive results of its proof-of-concept (POC) clinical trial for TVGN 489, the use of Artificial Intelligence in its process and future manufacturing capabilities. During the meeting, Tevogen Bio discussed ExacTcell\u2019s unique ability to rapidly adapt to emerging viral threats, positioning it as a potential countermeasure to safeguard public health. Tevogen Bio will follow up with key federal entities and continue to update stakeholders. VITAL Biotech Accelerator Program Department of Defense &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell\u2122 Technology\u2019s Potential as a Scalable Medical Countermeasure&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-810598","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell\u2122 Technology\u2019s Potential as a Scalable Medical Countermeasure - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell\u2122 Technology\u2019s Potential as a Scalable Medical Countermeasure - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WARREN, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) &#8212; Tevogen Bio (\u201cTevogen Bio Holdings Inc.\u201d or \u201cCompany\u201d) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, met the Center for the Biomedical Advanced Research and Development Authority (BARDA) TechWatch team. The discussion focused on Tevogen Bio\u2019s affordable and scalable ExacTcell technology, the positive results of its proof-of-concept (POC) clinical trial for TVGN 489, the use of Artificial Intelligence in its process and future manufacturing capabilities. During the meeting, Tevogen Bio discussed ExacTcell\u2019s unique ability to rapidly adapt to emerging viral threats, positioning it as a potential countermeasure to safeguard public health. Tevogen Bio will follow up with key federal entities and continue to update stakeholders. VITAL Biotech Accelerator Program Department of Defense &hellip; Continue reading &quot;Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell\u2122 Technology\u2019s Potential as a Scalable Medical Countermeasure&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-07T20:00:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NTEwNiM2NzQxNjA5IzIyODk5MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell\u2122 Technology\u2019s Potential as a Scalable Medical Countermeasure\",\"datePublished\":\"2025-02-07T20:00:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\\\/\"},\"wordCount\":379,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NTEwNiM2NzQxNjA5IzIyODk5MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\\\/\",\"name\":\"Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell\u2122 Technology\u2019s Potential as a Scalable Medical Countermeasure - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NTEwNiM2NzQxNjA5IzIyODk5MTc=\",\"datePublished\":\"2025-02-07T20:00:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NTEwNiM2NzQxNjA5IzIyODk5MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NTEwNiM2NzQxNjA5IzIyODk5MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell\u2122 Technology\u2019s Potential as a Scalable Medical Countermeasure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell\u2122 Technology\u2019s Potential as a Scalable Medical Countermeasure - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\/","og_locale":"en_US","og_type":"article","og_title":"Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell\u2122 Technology\u2019s Potential as a Scalable Medical Countermeasure - Market Newsdesk","og_description":"WARREN, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) &#8212; Tevogen Bio (\u201cTevogen Bio Holdings Inc.\u201d or \u201cCompany\u201d) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, met the Center for the Biomedical Advanced Research and Development Authority (BARDA) TechWatch team. The discussion focused on Tevogen Bio\u2019s affordable and scalable ExacTcell technology, the positive results of its proof-of-concept (POC) clinical trial for TVGN 489, the use of Artificial Intelligence in its process and future manufacturing capabilities. During the meeting, Tevogen Bio discussed ExacTcell\u2019s unique ability to rapidly adapt to emerging viral threats, positioning it as a potential countermeasure to safeguard public health. Tevogen Bio will follow up with key federal entities and continue to update stakeholders. VITAL Biotech Accelerator Program Department of Defense &hellip; Continue reading \"Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell\u2122 Technology\u2019s Potential as a Scalable Medical Countermeasure\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-07T20:00:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NTEwNiM2NzQxNjA5IzIyODk5MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell\u2122 Technology\u2019s Potential as a Scalable Medical Countermeasure","datePublished":"2025-02-07T20:00:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\/"},"wordCount":379,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NTEwNiM2NzQxNjA5IzIyODk5MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\/","name":"Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell\u2122 Technology\u2019s Potential as a Scalable Medical Countermeasure - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NTEwNiM2NzQxNjA5IzIyODk5MTc=","datePublished":"2025-02-07T20:00:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NTEwNiM2NzQxNjA5IzIyODk5MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NTEwNiM2NzQxNjA5IzIyODk5MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-bio-meets-barda-techwatch-team-highlighting-exactcell-technologys-potential-as-a-scalable-medical-countermeasure\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell\u2122 Technology\u2019s Potential as a Scalable Medical Countermeasure"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/810598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=810598"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/810598\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=810598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=810598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=810598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}